Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients
- PMID: 3756312
Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients
Abstract
Bestatin, an immunostimulating substance of microbial origin, was examined for its capacity to augment immune responses of blood lymphocytes in bladder cancer patients having received a full course of local irradiation (64 Gy). Following irradiation the patients became lymphopenic and the lymphocytes exhibited impaired mitogenic responses to phytohemagglutinin (PHA) and purified protein derivative of tuberculin (PPD) and reduced poke weed mitogen induced secretion of immunoglobulins in vitro. Patients who were randomized to receive daily oral Bestatin treatment exhibited enhanced recoveries of PHA- and PPD-responses and enhanced recovery of the IgM secreting capacity compared to irradiated patients who did not receive Bestatin. Repopulation of the blood lymphocyte population, however, was not enhanced by Bestatin treatment. It is concluded that Bestatin treatment may enhance the recovery of radiation induced functional defects of the immune system in cancer patients.
Similar articles
-
Immunological and haematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trial.Biomed Pharmacother. 1984;38(3):143-9. Biomed Pharmacother. 1984. PMID: 6383491 Clinical Trial.
-
[The immunomodulating action of bestatin in the combined therapy of bladder cancer patients].Urol Nefrol (Mosk). 1994 Mar-Apr;(2):34-8. Urol Nefrol (Mosk). 1994. PMID: 8017004 Russian.
-
Partial review of immunotherapeutic pharmacology in stem cell transplantation.In Vivo. 2000 Jan-Feb;14(1):221-36. In Vivo. 2000. PMID: 10757081 Clinical Trial.
-
Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.Behring Inst Mitt. 1984 May;(74):157-73. Behring Inst Mitt. 1984. PMID: 6383322 Review.
-
Clinical trials of bestatin for leukemia and solid tumors.Biotherapy. 1992;4(3):205-14. doi: 10.1007/BF02174207. Biotherapy. 1992. PMID: 1599804 Review.
Cited by
-
Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.Med Sci Monit. 2018 Aug 20;24:5811-5819. doi: 10.12659/MSM.909865. Med Sci Monit. 2018. PMID: 30125265 Free PMC article.
-
Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial.Cancer Immunol Immunother. 1987;25(1):41-6. doi: 10.1007/BF00199299. Cancer Immunol Immunother. 1987. PMID: 3594491 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical